MissionIR Articles
-
MissionIRNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Co-Founder and CEO Showcases XPro1595 at Maxim Group’s Conference on Alzheimer’s Disease
INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its co-founder and CEO, R.J. Tesi, M.D., presented at…
-
MissionIRNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) at the Forefront of Modernizing Immunology
Diversified clinical-stage immunology company INmune Bio (NASDAQ: INMB) is on a mission to develop novel immunotherapies that reprogram patients’ innate immune systems to enable them to fight cancer and Alzheimer’s disease. A recent article further…
-
MissionIRNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Developing Innovative Drug Candidates to Treat Cancer, Alzheimer’s Disease
INmune Bio (NASDAQ: INMB), a diversified clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to combat disease, is currently developing drug candidates INKmune and INB03, which may be used…
-
MissionIRNewsBreaks – Why INmune Bio Inc. (NASDAQ: INMB) Is ‘One to Watch’
INmune Bio (NASDAQ: INMB) is a diversified clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to combat disease. An article further discussing the company reads, “Drug candidates INKmune and…
-
INmune Bio Inc. (NASDAQ: INMB) Focusing on New Immunotherapies that Reprogram Immune Systems
INmune Bio is at the vanguard of reprogramming the innate immune system for the treatment of disease The company’s focus is on modulating components of the innate immune system to treat cancer and Alzheimer’s disease…
-
MissionIRNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) to Showcase Alzheimer’s Drug Candidate XPro1595 at TNF Conference
INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, on Tuesday announced that its director of neuroscience, CJ Barnum, Ph.D., will be…
-
INmune Bio Inc. (NASDAQ: INMB) to Offer Updates on Novel Immunotherapies During LD Micro Invitational
A presentation by INMB co-founder and CFO David Moss is slated for June 5 at 10:20 a.m., with one-on-one meetings also available The company’s active drug candidates are INKmune and INB03, which may be used…
-
INmune Bio Inc. (NASDAQ: INMB) Developing Novel Immunotherapies Targeting Alzheimer’s Disease, Cancer
INmune Bio is a diversified, clinical stage immunology company developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease Drug candidates INKmune and INB03 may be used to treat cancer;…
-
INmune Bio Inc. (NASDAQ: INMB) is “One to Watch”
INmune Bio’s IPO closed February 1, 2019, with NASDAQ Capital Markets listing on February 4, 2019 Public clinical-stage immunology company with programs in oncology and neurodegenerative disease INmune Bio targets large markets with unsolved problems…
-
MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at Ninth Annual LD Micro Invitational on June 5
INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that its co-founder and CFO David Moss will present at the Ninth…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Duos Technologies Group, Inc. (NASDAQ: DUOT) Prices $65M Public Offering to Advance Edge Data Center Expansion
- MissionIRNewsBreaks – ClearThink 1 Acquisition Corp. (NASDAQ: CTAAU) Closes $125M Initial Public Offering
- MissionIRNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Reports Surge in Institutional Ownership as Platform Expansion Accelerates
- Forward Industries Inc. (NASDAQ: FWDI) Executes the Company’s Solana Treasury Strategy to Build on a Successful 2026 Fiscal Q1
- MissionIRNewsBreaks – Olenox Industries (NASDAQ: OLOX) Launches 2026 Drilling Program, Targets 1,000 BOE per Day by Year-End